MJ
Meckler Jeffrey A
首席执行官
C-suiteM
内部人交易记录
首席执行官基于 4 个已确定 T+90 收益的买入信号。收益基准:公布次日的收盘价。
Browse the complete record of transactions filed by Meckler Jeffrey A, 首席执行官. Director active across 2 companies, notably Travere Therapeutics, Inc.. Cumulatively, 22 filings have been recorded. Split: 6 buys · 4 sells. Total volume traded: €1.4m. Activity tracked since 14 May 2021. The latest transaction was filed on 10 September 2026 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Meckler Jeffrey A
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报22 总计
10,000 股@ US$17.44Common StockSEC:0001506916-26-000004:0
10,000 股@ US$26.52Common StockSEC:0001506916-26-000004:1
1,700 股@ US$65.3917Common StockSEC:0001506916-26-000004:2
1,200 股@ US$66.15Common StockSEC:0001506916-26-000004:3
14,000 股@ US$67.4634Common StockSEC:0001506916-26-000004:4
3,100 股@ US$68.088Common StockSEC:0001506916-26-000004:5
216,617 股@ US$2.0345.9% 占其流量Common StockSEC:0001493152-25-029355:0
6,068 股@ US$8.30249.7% 占其流量Common StockSEC:0001641172-25-021376:0
6,500 股0Common StockSEC:0001415889-25-013500:0
42,553 股@ US$1.1759.0% 占其流量Common stockSEC:0001493152-24-047808:0
40,000 股@ US$10.48100.0% 占其流量Common StockSEC:0001415889-24-024117:0
84,932 股@ US$1.82526.9% 占其流量Common stockSEC:0001493152-24-030839:0
6,500 股0Common StockSEC:0001415889-24-012848:0
4,500 股0Common StockSEC:0001209191-23-030961:0
400 股@ US$1.76370.1% 占其流量Common stockSEC:0001493152-22-033241:0
10,308 股@ US$2.805.5% 占其流量Common stockSEC:0001493152-22-025578:0
1,060 股@ US$2.440.5% 占其流量Common stockSEC:0001493152-22-025319:0
19,727 股@ US$2.635.9% 占其流量Common stockSEC:0001493152-22-016027:0
3,000 股0Common StockSEC:0001209191-22-028697:0
11,187 股@ US$5.827.0% 占其流量Common StockSEC:0001493152-21-029297:0
12,000 股@ US$7.008.7% 占其流量Common StockSEC:0001493152-21-022936:0
3,000 股0Common StockSEC:0001209191-21-033849:0
About Meckler Jeffrey A
Meckler Jeffrey A is Président et Directeur Général. Across the 16 filings recorded, the most recent filings, from 2021-05-18 to 2025-12-29, show purchases of EUR 209315 and no sales, with the dominant transaction nature listed as Attribution. The main filings relate to Travere Therapeutics, Inc. and Indaptus Therapeutics, Inc.